Background: The CRASH-2 trial, published in 2010, showed a survival benefit for patients with traumatic hemorrhage who received TXA compared to placebo. TXA has become standard practice in many settings as a result of this data. However, patients with significant ...
Background: Acute gastrointestinal bleeding (GIB) is a common diagnosis dealt with by emergency clinicians. Definitive therapy for acute GIB often includes endoscopy or surgery. However, there is a myriad of pharmaceutical options (i.e. PPI, Somatostatin Analogues, Antibiotics, etc.) as well ...
Background: Evidence from the CRASH-2 trial showed an absolute reduction in mortality of 1.5% (NNT = 67) in patients with extracranial bleeding treated with tranexamic acid (TXA) within 3 hours of injury. However, CRASH-2 did not answer the question of ...
Background: TXA is a synthetic lysine derivative that binds with the lysine site on plasminogen and inhibits fibrinolysis. TXA is not a new drug. Studies from the late 1960s and early 1970s have shown reduced bleeding and need for transfusions in ...
Background: Bleeding from massive hemorrhage in trauma and post-partum are a major cause of death worldwide. There have been two large randomized controlled trials, in trauma and post-partum hemorrhage that have shown administration of TXA within 3 hrs of bleeding ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
